(Q37271427)

19 August 2017

1 reference

title

Therapy insight: Management of cardiovascular disease in patients with cancer and cardiac complications of cancer therapy (English)

1 reference

19 August 2017

main subject

cardiovascular disease

1 reference

Aarif Y Khakoo

1

1 reference

19 August 2017

Edward T H Yeh

series ordinal

2

1 reference

19 August 2017

publication date

16 September 2008

1 reference

Nature Clinical Practice Oncology

19 August 2017

published in

1 reference

19 August 2017

volume

5

1 reference

19 August 2017

issue

11

1 reference

19 August 2017

page(s)

655-667

1 reference

Radiation-induced cardiovascular diseases: is the epidemiologic evidence compatible with the radiobiologic data?

19 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1225

Risk factors for doxorubicin-induced congestive heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1225

Reduction of doxorubicin cardiotoxicity by prolonged continuous intravenous infusion

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1225

High-dose ifosfamide is associated with severe, reversible cardiac dysfunction

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1225

The polymorphonuclear leukocyte and the abdominal aortic aneurysm: a neglected cell type and a neglected disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1225

7 January 2021

Cardiotoxicity induced by chemotherapy and antibody therapy

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1225

7 January 2021

Molecular basis of anthracycline-induced cardiotoxicity and its prevention

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1225

7 January 2021

The cardioprotective effect of the iron chelator dexrazoxane (ICRF-187) on anthracycline-mediated cardiotoxicity.

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1225

7 January 2021

A clinicopathologic analysis of adriamycin cardiotoxicity

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1225

7 January 2021

Cardiac toxicity 4 to 20 years after completing anthracycline therapy

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1225

7 January 2021

Congestive heart failure in patients treated with doxorubicin: a retrospective analysis of three trials

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1225

7 January 2021

Congestive heart failure and left ventricular dysfunction complicating doxorubicin therapy. Seven-year experience using serial radionuclide angiocardiography

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1225

7 January 2021

ACC/AHA/ASE 2003 Guideline Update for the Clinical Application of Echocardiography: Summary Article: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/ASE Committee to Update the 1997

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1225

7 January 2021

Tissue Doppler imaging and conventional echocardiography after anthracycline treatment in adults: early and late alterations of left ventricular function during a prospective study.

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1225

7 January 2021

Efficacy and cost of cardiac monitoring in patients receiving doxorubicin

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1225

7 January 2021

Underlying causes and long-term survival in patients with initially unexplained cardiomyopathy

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1225

7 January 2021

Prevention of high-dose chemotherapy-induced cardiotoxicity in high-risk patients by angiotensin-converting enzyme inhibition

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1225

7 January 2021

Cardiac troponin I. A marker with high specificity for cardiac injury

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1225

7 January 2021

cTnT can be a useful marker for early detection of anthracycline cardiotoxicity

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1225

7 January 2021

Prolonged monitoring of troponin T for the detection of anthracycline cardiotoxicity in adults with hematological malignancies

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1225

7 January 2021

Myocardial injury revealed by plasma troponin I in breast cancer treated with high-dose chemotherapy

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1225

7 January 2021

Left ventricular dysfunction predicted by early troponin I release after high-dose chemotherapy

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1225

7 January 2021

Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1225

7 January 2021

Elevated B-type natriuretic peptide levels after anthracycline administration

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1225

7 January 2021

B-type natriuretic peptide as a marker for cardiac dysfunction in anthracycline-treated children.

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1225

7 January 2021

Cancer patients with markedly elevated B-type natriuretic peptide may not have volume overload.

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1225

7 January 2021

Relationship between B-type natriuretic peptides and pulmonary capillary wedge pressure in the intensive care unit.

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1225

7 January 2021

Does anthracycline administration by infusion in children affect late cardiotoxicity?

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1225

7 January 2021

Epirubicin. An updated review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in the management of breast cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1225

7 January 2021

A randomized comparison of the efficacy and toxicity of epirubicin and doxorubicin in the treatment of patients with non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1225

7 January 2021

Mitoxantrone: an overview of safety and toxicity

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1225

7 January 2021

Late cardiac toxicity of doxorubicin, epirubicin, and mitoxantrone therapy for Hodgkin's disease in adults

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1225

7 January 2021

Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX/Doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1225

7 January 2021

Pegylated liposomal doxorubicin (doxil): reduced clinical cardiotoxicity in patients reaching or exceeding cumulative doses of 500 mg/m2.

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1225

7 January 2021

ICRF-187 permits longer treatment with doxorubicin in women with breast cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1225

7 January 2021

Cardioprotective interventions for cancer patients receiving anthracyclines

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1225

7 January 2021

Cardioprotection with dexrazoxane for doxorubicin-containing therapy in advanced breast cancer.

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1225

7 January 2021

2002 update of recommendations for the use of chemotherapy and radiotherapy protectants: clinical practice guidelines of the American Society of Clinical Oncology

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1225

7 January 2021

Carvedilol prevents doxorubicin-induced free radical release and apoptosis in cardiomyocytes in vitro

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1225

7 January 2021

Protective effects of carvedilol against doxorubicin-induced cardiomyopathy in rats

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1225

7 January 2021

Carvedilol protects against doxorubicin-induced mitochondrial cardiomyopathy

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1225

7 January 2021

Protective effects of carvedilol against anthracycline-induced cardiomyopathy

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1225

7 January 2021

Simultaneous angiotensin converting enzyme inhibition moderates ventricular dysfunction caused by doxorubicin

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1225

7 January 2021

Cardioprotective effects of zofenopril, a new angiotensin-converting enzyme inhibitor, on doxorubicin-induced cardiotoxicity in the rat.

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1225

7 January 2021

Cardiac toxicity of high-dose cyclophosphamide in patients with multiple myeloma undergoing autologous hematopoietic stem cell transplantation

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1225

7 January 2021

Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1225

7 January 2021

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1225

7 January 2021

Long-term cardiac tolerability of trastuzumab in metastatic breast cancer: the M.D. Anderson Cancer Center experience

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1225

7 January 2021

Assessment of Cardiac Dysfunction in a Randomized Trial Comparing Doxorubicin and Cyclophosphamide Followed by Paclitaxel, With or Without Trastuzumab As Adjuvant Therapy in Node-Positive, Human Epidermal Growth Factor Receptor 2–Overexpressing Bre

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1225

7 January 2021

Adjuvant therapy with trastuzumab for HER-2/neu-positive breast cancer.

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1225

7 January 2021

Cardiovascular complications of cancer therapy: diagnosis, pathogenesis, and management

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1225

7 January 2021

Reversibility of trastuzumab-related cardiotoxicity: new insights based on clinical course and response to medical treatment

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1225

7 January 2021

Molecular mechanisms of cardiotoxicity of tyrosine kinase inhibition

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1225

7 January 2021

Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1225

7 January 2021

Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1225

7 January 2021

Cardiotoxicity of the cancer therapeutic agent imatinib mesylate.

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1225

7 January 2021

Congestive heart failure is a rare event in patients receiving imatinib therapy

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1225

7 January 2021

Imatinib does not induce cardiac left ventricular failure in gastrointestinal stromal tumours patients: Analyis of EORTC-ISG-AGITG study 62005

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1225

7 January 2021

Terminal ballistics of kinase inhibitors: there are no magic bullets

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1225

7 January 2021

Food and Drug Administration drug approval summary: Sunitinib malate for the treatment of gastrointestinal stromal tumor and advanced renal cell carcinoma.

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1225

7 January 2021

Sunitinib in patients with metastatic renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1225

7 January 2021

Expert consensus document on beta-adrenergic receptor blockers

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1225

7 January 2021

The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1225

7 January 2021

Current guidelines for treatment of heart failure: 2006 update

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1225

7 January 2021

The effect of digoxin on mortality and morbidity in patients with heart failure

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1225

7 January 2021

https://api.crossref.org/works/10.1038%2FNCPONC1225

1 reference

7 January 2021

Cardiac resynchronization therapy for patients with left ventricular systolic dysfunction: a systematic review

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1225

7 January 2021

Cardiotoxicity of high-dose continuous infusion fluorouracil: a prospective clinical study

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1225

7 January 2021

Cardiac toxicity of 5-fluorouracil: a study on 1083 patients.

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1225

7 January 2021

Cardiotoxicity of fluoropyrimidines in different schedules of administration: a prospective study

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1225

7 January 2021

Myocardial infarction following vinblastine treatment

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1225

7 January 2021

Vincristine-induced myocardial infarction

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1225

7 January 2021

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1225

7 January 2021

Treatment of advanced non-small-cell lung cancer in the elderly: results of an international expert panel

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1225

7 January 2021

Pathophysiological effects of radiation on atherosclerosis development and progression, and the incidence of cardiovascular complications

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1225

7 January 2021

Severe coronary artery disease after radiation therapy of the chest and mediastinum: clinical presentation and treatment

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1225

7 January 2021

Clinical and angiographic features of coronary artery disease after chest irradiation

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1225

7 January 2021

Valvular dysfunction and carotid, subclavian, and coronary artery disease in survivors of hodgkin lymphoma treated with radiation therapy

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1225

7 January 2021

Mortality from myocardial infarction following postlumpectomy radiotherapy for breast cancer: a population-based study in Ontario, Canada

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1225

7 January 2021

A population-based case-cohort study of the risk of myocardial infarction following radiation therapy for breast cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1225

7 January 2021

Cardiovascular mortality in a randomized trial of adjuvant radiation therapy versus surgery alone in primary breast cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1225

7 January 2021

Mortality from myocardial infarction after adjuvant radiotherapy for breast cancer in the surveillance, epidemiology, and end-results cancer registries

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1225

7 January 2021

Screening for Coronary Artery Disease After Mediastinal Irradiation for Hodgkin's Disease

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1225

7 January 2021

MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1225

7 January 2021

Long-term mortality from heart disease and lung cancer after radiotherapy for early breast cancer: prospective cohort study of about 300,000 women in US SEER cancer registries

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1225

7 January 2021

Radiation-induced heart disease: vigilance is still required

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1225

7 January 2021

5-Fluorouracil cardiotoxicity: left ventricular dysfunction and effect of coronary vasodilators

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1225

7 January 2021

Coronary angioplasty with or without stent implantation for acute myocardial infarction. Stent Primary Angioplasty in Myocardial Infarction Study Group

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1225

7 January 2021

Late thrombosis in drug-eluting coronary stents after discontinuation of antiplatelet therapy.

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1225

7 January 2021

Contemporary evaluation and management of hypertrophic cardiomyopathy

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1225

7 January 2021

Impact of aspirin therapy in cancer patients with thrombocytopenia and acute coronary syndromes

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1225

7 January 2021

Intensive versus moderate lipid lowering with statins after acute coronary syndromes

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1225

7 January 2021

Identifiers

DOI

10.1038/NCPONC1225

1 reference

19 August 2017

1 reference